Search
Secale cereale pollen
go.drugbank.com/drugs/DB10717ApprovedSecale cereale pollen is the pollen of the Secale cereale plant. Secale cereale pollen is mainly used in allergenic testing.
Mixtures: Treatment Set TS333938, Treatment Set TS128872Ritlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigational[L47092,L47127] It was further approved by the EMA in September 2023.[L48181] Ritlecitinib is administered orally and is the first member of its class.
VB10.16
go.drugbank.com/drugs/DB17512InvestigationalIt is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting
Pipequaline
go.drugbank.com/drugs/DB13991ExperimentalIt presents a unique chemical structure that does not follow the structural properties of other drugs of its class. … However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic or anticonvulsant effect.
Endometrial Hyperplasia
go.drugbank.com/conditions/DBCOND0001317Synonyms: Complex endometrial hyperplasia (disorder)CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalThe antimicrobial activity of CZEN-002 is unique in that it does not depend on direct damage to the microbial membrane. … Studies attempting to understand the candidacidal activity of derivatives of alpha-MSH have focused on the alpha-MSH amino acid sequence (6-13), which contains the invariant core sequence His-Phe-Arg-Trp
Arasertaconazole
go.drugbank.com/drugs/DB19151InvestigationalArasertaconazole is under investigation in clinical trial NCT01144286 (Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment).
Ipafricept
go.drugbank.com/drugs/DB15045InvestigationalIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
Artemin
go.drugbank.com/drugs/DB15438InvestigationalArtemin is under investigation in clinical trial NCT01842126 (Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)).